

Index

A

- Adaptive immune system, 81, 82, 94
- Adoptive cellular immunotherapy (ACT)
 - improvement of, 38
- Antigen presenting cells (APC), 7, 32–34, 36, 43, 44, 46, 61, 63, 75
- Antiviral activity, 2, 6, 8

C

- CD4 T cells, 21
- CD8+ T cell, 10, 45–49
- CD8+ T cell, 73, 76, 77, 82, 87
 - memory, non-cognate differentiation into robust effector cells, 74, 75
- CD8 T cell responses, 34–38, 143
 - expansion and contraction of, 32, 33
 - initiation of, 32
 - primary, signals that guide, 33
- CX3CR1, 63–66, 97
- Cytokine expression, 46
- Cytokine signals, 85
 - and costimulatory/coinhibitory receptors, interplay between, 24, 25
- Cytokine stimulation, 33, 34, 85

D

- Dendritic cells (DCs), 32
 - discovery and their exploration in man, 44, 45
 - intestinal, 94, 96, 104, 106–108, 110
 - kidney, 67
 - monocyte-derived, 3
 - plasmacytoid, 3, 25
 - subset
 - specializations of, 46
 - specific skin, 45, 46

Dendritic cells (DCs):subset

- human
 - T helper polarization by, 48
- mouse
 - T helper polarization by, 48
- Dermal CD14+DCs, 46, 48
- Dietary antigens, 94, 101–103, 109
 - recognition by the intestinal immune system, 95–98

G

- Glomerulonephritis (GN), 62
 - and the model of nephrotoxic nephritis, 58, 59
- Gut-associated lymphoid tissues (GALT), 94–96

I

- Infections
 - chronic
 - T cell exhaustion in, stable and flexible features of, 145, 146
 - T cell responses in, mechanisms that maintain, 143–145
- LCMV
 - milestone achievements obtained by, 139–141
- Inflammation
 - antigen-driven clonal expansion in NK cells, 85–87
 - type-1
 - Treg subsets divergent role in, 19
- Inflammatory cytokines, 33, 84, 85
- Inflammatory kidney disease, 58
- Innate immune system, 81, 82

Interleukin 12 (IL-12), 7–9, 20, 22, 35–37
 Interleukin 28 (IL-28)
 IL-28A, 2
 IL-28B, 2
 Interleukin 29 (IL-29), 2
 Interstitial nephritis (tubulointerstitium), 58
 and the model of bacterial pyelonephritis,
 59–62
 Intestinal DCs, 94, 96, 104, 106–108, 110
 Intestinal immune system, 94, 109
 recognition of dietary antigens by, 95–98

K

Kidney DCs, 67
 Kidney physiology, 57, 58

L

Lambda interferons (IFN- λ s), 2–7
 in mucosal immunity, 7, 8
 other functions of, 8, 9
 therapeutic opportunities using, 9, 10
 Langerhans Cells (LCs), 44, 45
 controversial role in mouse and human,
 49, 50
 Lymphocytic choriomeningitis virus (LCMV),
 6, 34–37, 138, 139
 clone 13 infection, 142–144
 infection model, 139, 147

M

Memory CD8 T cells, 33, 138, 140, 141
 Mouse DCs, 43, 47, 48
 Mucosal immunity
 IFN- λ s in, 7, 8

N

NK cell memory, 84

R

Regulatory T cells (Tregs), 18, 19, 99, 102,
 104
 type-1 cytokines effects on, 20, 21, 23

T

T cell exhaustion, 145
 in chronic infections, stable and flexible
 features of, 145, 146
 Th1 cells, 19, 22, 25
 Th1-like, 19, 20, 22, 25
 Th1-suppressing, 18, 19, 22, 23, 25
 Translational research, 137
 Type-I cytokines, 18, 19, 26
 effect on Tregs, 20, 21, 23
 Type I IFN, 3
 Type III Interferons (INF)\t See Lambda
 interferons (IFN- λ s), 1
 Type I Interferon (IFN), 1, 3, 4, 6, 7, 10, 35